Shares of orphan drugmaker NPS Pharmaceuticals (UNKNOWN:NPSP.DL) are up more than 4% in intraday trading. The company, which gained Food and Drug Adminstration approval for its short bowel syndrome drug Gattex back in December, reported its first-quarter earnings and revealed the prescription numbers and sales of its drug launch. In the following video, health care analyst Max Macaluso discusses these details and three key takeaways from the company's first quarter.
- May 9, 2013 at 3:12PM
- Health Care